Starpharma Current ratio
Cos'è Current ratio di Starpharma?
Current ratio di Starpharma Holdings Limited è 4.94
Qual è la definizione di Current ratio?
Il rapporto corrente è un rapporto di liquidità che misura se una società dispone o meno di risorse sufficienti per soddisfare i suoi obblighi a breve termine.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio di aziende nel Health Care settore su ASX rispetto a Starpharma
Cosa fa Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Aziende con current ratio simili a Starpharma
- Tristel Plc ha Current ratio di 4.93
- Musgrave Minerals ha Current ratio di 4.93
- The Mandhana Retail Ventures ha Current ratio di 4.93
- ACON S2 Acquisition ha Current ratio di 4.93
- Tamawood ha Current ratio di 4.93
- Vitreous Glass ha Current ratio di 4.93
- Starpharma ha Current ratio di 4.94
- Civitas Social Housing Plc ha Current ratio di 4.94
- China Outfitters ha Current ratio di 4.95
- Uranium Participation ha Current ratio di 4.95
- Uranium Participation ha Current ratio di 4.95
- NexPoint Residential Trust Inc ha Current ratio di 4.95
- CARE Ratings ha Current ratio di 4.95